(Q32039000)

5 July 2017

title

Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine (English)

1 reference

5 July 2017

1 reference

1 reference

1 reference

M L Christensen

1

1 reference

5 July 2017

S K Eades

2

1 reference

5 July 2017

E Fuseau

3

1 reference

5 July 2017

R D Kempsford

4

1 reference

5 July 2017

S J Phelps

5

1 reference

5 July 2017

L J Hak

6

1 reference

5 July 2017

language of work or name

1 reference

1 February 2001

1 reference

The Journal of Clinical Pharmacology

5 July 2017

published in

1 reference

5 July 2017

volume

41

1 reference

5 July 2017

issue

2

1 reference

5 July 2017

page(s)

170-175

1 reference

Classification of pediatric migraine: proposed revisions to the IHS criteria

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

An epidemiologic study of headache among adolescents and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

The migraine syndrome in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

Clinical and demographic characteristics of migraine in urban children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

5-Hydroxytryptamine and the pathophysiology of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

Naratriptan: biological profile in animal models relevant to migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

Sumatriptan. An updated review of its use in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

IHS Criteria for Migraine and Tension-Type Headache in Children and Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009980

10.1177/00912700122009980

21 January 2018

Identifiers

DOI

1 reference

5 July 2017

1 reference